CytomX Therapeutics Insider Trades
NASDAQ: CTMXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Last 12 months
- Purchases
- 0 · $0
- Sales
- 5 · $1.23M
- Shares bought / sold
- 0 / 192.69K
- Net activity
- Net selling $1.2 million
CytomX Therapeutics insider activity
Over the last 12 months, CytomX Therapeutics insiders reported 11 transactions on SEC Form 4: 0 open-market purchases and 5 sales. Insiders bought $0 and sold $1.2 million worth of stock, for net insider selling of $1.2 million. The largest seller was McCarthy Sean A., with $764,138 in reported sales.
The most recent filing shows Carvajal Alejandra (Chief Legal Officer) reporting a transaction in 100,000 shares on Aug 3, 2026. Insider sales are common for compensation, tax and diversification reasons, while open-market purchases are rarer; tracking both helps put CTMX's ownership changes in context.
Summary generated from market data by MetaCap's automated system. Methodology
CTMX insider transactions
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Aug 3, 2026 | Carvajal AlejandraChief Legal Officer | Award | 100,000 | — | Form 4 |
| Jun 15, 2026 | Ogden ChristopherChief Financial Officer | Sale | 1,624 | $4.95K | Form 4 |
| Mar 17, 2026 | Ogden ChristopherChief Financial Officer | Sale | 19,323 | $124.11K | Form 4 |
| Mar 17, 2026 | BELVIN MARCIASVP, Chief Scientific Officer | Sale | 31,492 | $202.27K | Form 4 |
| Mar 17, 2026 | McCarthy Sean A.CEO | Sale | 118,969 | $764.14K | Form 4 |
| Mar 17, 2026 | Chu Yu-WayeChief Medical Officer | Sale | 21,279 | $136.68K | Form 4 |
| Feb 2, 2026 | McCarthy Sean A.CEO | Award | 210,000 | — | Form 4 |
| Feb 2, 2026 | Ogden ChristopherChief Financial Officer | Award | 90,000 | — | Form 4 |
| Feb 2, 2026 | BELVIN MARCIASVP, Chief Scientific Officer | Award | 60,000 | — | Form 4 |
| Feb 2, 2026 | Chu Yu-WayeChief Medical Officer | Award | 75,000 | — | Form 4 |
| Feb 2, 2026 | Lester RachaelChief Business Officer | Award | 20,000 | — | Form 4 |
| Nov 6, 2025 | McCarthy Sean A.CEO | Sale | 101,793 | $461.91K | Form 4 |
| Nov 6, 2025 | McCarthy Sean A.CEO | Sale | 101,793 | $461.91K | Form 4 |
| Nov 6, 2025 | McCarthy Sean A.CEO | Option exercise | 101,793 | $161.85K | Form 4 |
| Jun 16, 2025 | BELVIN MARCIASVP, Chief Scientific Officer | Sale | 13,884 | $37.33K | Form 4 |
| Jun 16, 2025 | Ogden ChristopherChief Financial Officer | Sale | 10,614 | $28.54K | Form 4 |
| Jun 16, 2025 | McCarthy Sean A.CEO | Sale | 55,511 | $149.26K | Form 4 |
| Jun 13, 2025 | BELVIN MARCIASVP, Chief Scientific Officer | Option exercise | 37,500 | — | Form 4 |
| Jun 13, 2025 | Ogden ChristopherChief Financial Officer | Option exercise | 37,500 | — | Form 4 |
| Jun 13, 2025 | Ogden ChristopherChief Financial Officer | Sale | 1,641 | $4.84K | Form 4 |
| Jun 13, 2025 | McCarthy Sean A.CEO | Option exercise | 150,000 | — | Form 4 |
| Mar 18, 2025 | BELVIN MARCIASVP, Chief Scientific Officer | Sale | 19,512 | $11.69K | Form 4 |
| Mar 18, 2025 | ROWLAND LLOYD AGeneral Counsel | Sale | 10,203 | $6.11K | Form 4 |
| Mar 18, 2025 | McCarthy Sean A.CEO | Sale | 37,656 | $22.56K | Form 4 |
| Mar 18, 2025 | Chu Yu-WayeChief Medical Officer | Sale | 4,025 | $2.41K | Form 4 |
| Mar 18, 2025 | Ogden ChristopherChief Financial Officer | Sale | 8,551 | $5.12K | Form 4 |
Transaction codes follow SEC Form 4: P = open-market purchase, S = open-market sale, A = grant or award, M = option exercise, F = shares withheld for taxes. About Form 4